Nektar Therapeutics Stock News

Wall Street brokerages forecast that Nektar Therapeutics (NASDAQ:NKTR) will post earnings per share (EPS) of ($0.75) for the current quarter, Zacks reports. Seven analysts have provided estimates for

Sean McCarthy, president and CEO of CytomX Therapeutics Inc.

ReAlta Life Sciences, Inc., a biotech company dedicated to harnessing the power of the immune system through its PIC1 technology platform to address life-threatening medical needs, today announced tha

Macquarie Group Ltd. grew its position in shares of Nektar Therapeutics (NASDAQ:NKTR) by 1.3% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 17

Ladenburg Thalmann Financial Services Inc. grew its position in Nektar Therapeutics (NASDAQ:NKTR) by 10.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Secu

The "Chronic Lower Back Pain (CLBP) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Geode Capital Management LLC trimmed its position in Nektar Therapeutics (NASDAQ:NKTR) by 27.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities an

Alliancebernstein L.P. increased its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 14.2% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 307,895 shares of t

Advisors Asset Management Inc. trimmed its stake in Nektar Therapeutics (NASDAQ:NKTR) by 49.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commissio

Dublin, April 07, 2020 -- The "Chronic Lower Back Pain (CLBP) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to.

Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Nektar Therapeutics (NASDAQ:NKTR) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 25,675

We’ve put together this presentation of eight stocks that you can count on during this crisis or any crisis.

Raymond James & Associates grew its holdings in shares of Nektar Therapeutics (NASDAQ:NKTR) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commiss

Shareholders in Nektar Therapeutics (NASDAQ:NKTR) may be thrilled to learn that the analysts have just delivered a...

Celebrations may be in order for Nektar Therapeutics (NASDAQ:NKTR) shareholders, with the analysts delivering a...